corrections welcome
Contact CJC-1295 Telehealth
Editorial corrections, citation questions, and pointers to studies we have missed are all welcome. This is a publishing project, not a clinic — we cannot answer personal medical questions.
Reach the editors
Use the form below to reach the editors of CJC-1295 Telehealth. The kinds of messages we can act on: a citation that resolves to the wrong paper, a figure that needs correcting, a recent study worth adding, or a point where the DAC and no-DAC distinction reads less clearly than it should. We read every note and update the board when the evidence warrants it.
What we cannot do is answer personal medical questions. We are not a clinic, we do not employ clinicians, and we do not offer consultations, prescriptions, or treatment of any kind. Questions about whether to use CJC-1295, at what dose, or for what purpose are outside what this project does and outside what the published literature supports — there is no approved human use to advise on.
For anything touching your own health, the right destination is a licensed clinician who can review your situation directly. This site can tell you what the studies measured; it cannot tell you what to do with your body, and it will not pretend to.
What a useful correction looks like
Because everything here is built on cited sources, the most valuable messages point at a specific claim and a specific source. If a half-life figure, a fold-change, or a dose on one of these pages disagrees with the paper it cites, tell us which page and which reference number, and we will check it against the primary source and correct the board. The same goes for the regulatory framing: the WADA Section S2 status and the 2024 FDA Pharmacy Compounding Advisory Committee record are public documents, and we would rather fix a misreading quickly than leave it standing.
We also welcome pointers to studies we have missed, especially newer GHRH-analog pharmacology and any peer-reviewed work that sharpens the DAC-versus-no-DAC distinction. CJC-1295's literature is small enough that a single good paper can change what the digest should say. What we will not publish is promotional material, sourcing inquiries, or anything framed as a sale — this is a reading board for the research, and it stays one.